Public releases
2024

Guidance update for 2024

2024/07/08 - Financial public releases

Exceptional first-half growth and guidance raised for 2024

Read more

Virbac finalizes minority shares’ acquisition of Globion, an Indian poultry vaccines specialist

2024/07/02 - Financial public releases

Virbac finalizes minority shares’ acquisition of Globion, an Indian poultry vaccines specialistOn June 21, we finalized the acquisition of Globion's minority shares, bringing our stake to 100%. As planned, this transaction follows the acquisition of a 74% majority stake concluded on November 1, 2023.

Read more

2024 first quarter consolidated sales

2024/04/16 - Financial public releases

Building on the momentum of the second half of 2023, strong first-quarter revenue growth of +10.8% at constant exchange rates

Read more

Virbac acquired Sasaeah, a leading animal health player in Japan.

2024/04/02 - Financial public releases

Sasaeah.jpgOn April 1, we successfully completed the acquisition of Sasaeah. This strategic acquisition brings Virbac a leadership position in the farm animal vaccines market in Japan, notably in the cattle segment, and a large portfolio of pharmaceutical products for all the major species.

Read more

Virbac to take a leading position in Japan through the acquisition of Sasaeah

2024/03/06 - Financial public releases

Sasaeah.jpgVirbac announces that it has signed a definitive agreement with ORIX Corporation for the acquisition of its animal health subsidiary Sasaeah for an enterprise value of approximately €280 million.

Read more

2023 fourth quarter consolidated sales

2024/01/17 - Financial public releases

Annual revenue growth of +4.9% thanks to record fourth-quarter activity at +11.5%

Read more